Interventional Glaucoma

Dr Khouri discusses selective laser trabeculoplasty (SLT) as a first-line treatment for glaucoma and identifies patients who would be good candidates for this procedure.

Dr Albert S Khouri, MD presents a case of a glaucoma patient and discusses his approach to medical management of glaucoma.

Danny A. Mammo, MD, sat down with Sydney Crago, Assistant Managing Editor of Modern Retina, to discuss his presentation on intraocular pressure outcomes following suprachoroidal triamcinolone acetonide in patients with glaucoma at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Researchers indicate that minimally invasive treatment with NurExon Biologic’s ExoPTEN showed functional restoration of damaged eyes to healthy levels in animals.

According to the company, FYSX is the first non-pharmacological, non-surgical treatment designed to lower IOP for glaucoma patients.

Technology offers increased usability, safety, and accuracy in MIGS procedures.

The deal included a total upfront consideration of $81 million, including a cash payment of approximately $65 million.

The patient-facing brochure serves as a vehicle to help ECPs review the solution’s information and prescription filling process with patients during and after an office visit, and the website serves as an additional resource and reference once the patient returns home.

A team of Korean researchers has examined data from the Korean National Health Information Database to determine whether subjects with allergic diseases exhibited a higher incidence of primary open-angle glaucoma compared to a control group.

All R&D for the drug will stop after the Phase 2a clinical trial failed to meet its primary endpoint of lowering IOP in patients with primary open-angle glaucoma.

McDonnell stays focused on helping the next generation of ophthalmologists launch their careers in academics.

The company’s KDB GLIDE is indicated for the excision of trabecular meshwork tissue to reduce intraocular pressure in adult patients with primary open-angle glaucoma during cataract surgery or as a stand-alone procedure.

The campaign will encourage, educate and empower the public to include vision and eye health as a part of their healthcare by asking them to share how eye care services and exams improved their vision and their daily lives.

Alcon agreed to acquire Belkin Vision and the Belkin Vision Eagle and plans to provide additional details when the deal is closed.

A team of Chinese researchers have been working on a way to continuously and more comfortably detect these tiny fluctuations in pressure, such as contact lenses that transmit signals to receptor glasses.

A singular celebration of science over the decades

From surgeon to mentor: Smith fuels her commitment to improving glaucoma care by training future ophthalmologists.

In a presentation at the Association for Research in Vision and Ophthalmology 2024 annual meeting in Seattle, researchers detailed a novel shunt, which could potentially improve postoperative IOP control and lower the risk of vision-threatening issues.

Priorities can ensure optimal outcomes for patients diagnosed with diseases.

Deborah Ristvedt, DO, in her Controversies in Modern Eye Care presentation, discussed the evolution from traditional glaucoma treatments to novel therapies that target the trabecular meshwork and that aim to optimize IOP management without the need for multiple medications.

Inder Paul Singh, MD, highlights how early intervention, modern techniques, and reduced medication burden can improve outcomes and quality of life for patients with glaucoma in his presentation at the Controversies in Modern Eye Care conference.

The 18th annual Controversies in Modern Eye Care conference, held on May 4, 2024, in Los Angeles, was co-chaired by Neda Shamie, MD, and Arjan Hura, MD, with the aim of discussing the latest advancements in eye care.

Rick Lewis, chief medical officer of ViaLase, describes the company's nonincisional glaucoma treatment, showing promising safety and efficacy in studies and possibly paving the way for FDA approval.

Deborah Gess Ristvedt, DO, shares highlights from her presentation and what these real-world cases mean for clinicians and their patients with glaucoma.

UPFs include fast food, energy drinks and soda, sweets such as chocolates and candies and much more.

The switch may produce an additional 25% IOP reduction in mild to moderate forms of disease

Mark J. Gallardo, MD, highlighted the results from a phase 2 clinical trial of a travoprost intracameral implant in open-angle glaucoma or ocular hypertension.

The technology uses a superelastic, memory-shaped nitinol guide that facilitates up to 360-degree guided circumferential removal of the trabecular meshwork.

The investigators conducted a multicenter, prospective, open-label, phase 4 study in which they evaluated the patients’ and investigators’ impressions of the drug.